AEZS CEO is a very well-know person in the pharmaceutical industry
David A. Dodd Appointed President & Chief Executive Officer of Aeterna Zentaris Inc. Québec City, Canada, April 15, 2013 - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today that David A. Dodd has been appointed President and Chief Executive Officer of the Company, succeeding Juergen Engel, PhD. Mr. Dodd has also been appointed director on the Company's Board of Directors. Aeterna Zentaris Inc. is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. "With the appointment of David, we are taking an important first step in transforming Aeterna Zentaris from a company focused on R&D to a company focused on commercializing the promising compounds in our pipeline," said Juergen Ernst, Chairman of the Board of Directors. ... David is a strong, focused leader with the ability to motivate employees, and significantly enhance shareholder value. We are delighted that he is joining our management team, and we look forward to his leadership and stewardship of Aeterna Zentaris." "I am honored and excited to have the opportunity to lead Aeterna Zentaris," said Mr. Dodd. "Building on the existing strong R&D foundation, my focus will be to serve the needs of patients, shareholders and employees through successful development and commercialization of novel, differentiated products that enhance and may save lives. I am fully committed to rewarding our shareholders with sustained growth and future profitability. Moreover, I look forward to the challenge of moving this company forward, and working with its highly dedicated staff." Mr. Dodd's executive management experience in the pharmaceutical and biotechnology industries spans more than 35 years. From December 2007 to June 2009, Mr. Dodd was President, CEO and Chairman of BioReliance Corporation, a leading provider of biological safety and related testing services. From October 2006 to April 2009, he served as non-executive Chairman of Stem Cell Sciences Plc., where he oversaw the development and implementation of a strategic growth plan, implementation of an experienced executive team, and the sale of the Company to Stem Cells, Inc., in April 2009. During Mr. Dodd's six-year tenure as President, CEO and Director of Serologicals Corporation, the market value of that company increased from $85 million in June 2000 to an all-cash sale to Millipore Corporation in July 2006 for $1.5 billion. That successful transformation followed his five-year term as President and CEO of Solvay Pharmaceuticals, Inc. and as Chairman of its subsidiary Unimed Pharmaceuticals, Inc. Prior to that, Mr. Dodd held various senior management positions at Wyeth-Ayerst Laboratories, the Mead Johnson Laboratories Division at Bristol-Myers Squibb, and Abbott Laboratories. Currently, he serves as Chair, Board of Directors, of GeoVax, Inc., a biotechnology company developing innovative, patented HIV/AIDS vaccines; as a Director on the Board of Aruna Biomedical, a privately-held life science development company focused on the development and commercialization of stem cell research products and services; and, as a Director on the Board of PNP Therapeutics, a clinical stage company, developing a novel nucleoside-booster treatment for solid tumor mass cancers. He also serves as CEO of RiversEdge BioVentures LLC ("RiversEdge"), which he founded in 2009. RiversEdge is an investment and advisory firm focused on the life sciences and pharmaceutical industry. He is a frequently invited speaker and panelist at business and economic development conferences, as well as various conferences focused on the life sciences and pharmaceutical industry. He is a recipient of the Oglethorpe Award for UK-US Business Relationships, the Georgia BIO Industry Growth Award, and the FastTech 50 Growth Company Award (2000-2006) while leading Serologicals Corporation. Mr. Dodd holds Bachelor of Science and Master of Science degrees from Georgia State University, and completed the Harvard Business School of Advanced Management Program. His numerous public service activities include the American Foundation for Suicide Prevention, and the Board of Directors of the Institute of Bioengineering and Bioscience at Georgia Institute of Technology. ... Prof. Dr. Engel, who will pursue his passion in research and development, said, "I have enjoyed my years at Aeterna Zentaris, and I am confident the company is in good hands, and will thrive under the leadership of David Dodd." Shareholders are advised that, in place of Prof. Dr. Engel, Mr. Dodd will be one of the management nominees for directors at the Company's annual meeting of shareholders to be held on May 8, 2013. Management proxy holders intend to exercise the discretion granted in the proxies and vote in favour of the election of Mr. Dodd as a director at the shareholders' meeting. Board of Directors | GeoVax, Inc. www.geovax.com, 28 Aug 2014 [cached] David A. Dodd, Chairman ... David A. Dodd David Dodd is the Chief Executive Officer of RiversEdge BioVentures, an investment and advisory firm focused on life sciences and pharmaceuticals, which he founded in 2009. He has more than 35 years of executive experience in the healthcare industry. From December 2007 to June 2009, Mr. Dodd was president, CEO and chairman of BioReliance Corporation, an organization that provided biological safety testing, viral clearance testing, genetic and mammalian technology testing and laboratory animal diagnostic services testing. From October 2006 to April 2009, he served as non-executive chairman of Stem Cell Sciences Plc., where he oversaw board responsibilities, including the development of a strategic growth plan, executive team, operations plan and compliance with investment regulatory authorities. Before that, Mr. Dodd served as President, CEO and director of Serologicals Corporation. During his tenure there, the market value of Serologicals Corporation increased from $85 million in June 2000 to an all cash sale to Millipore Corporation in July 2006 for $1.5 billion. This achievement followed Mr. Dodd's five-year stint as president and CEO of Solvay Pharmaceuticals, Inc. and as chairman of its subsidiary Unimed Pharmaceuticals, Inc. Avista Capital Partners : News : [News Title] www.avistacap.com, 3 Dec 2007 [cached] David A. Dodd to Lead BioReliance Corporation Avista Capital Partners : News : [News Title] ... David A. Dodd to Lead BioReliance Corporation ... 12/3/2007 David A. Dodd to Lead BioReliance Corporation ROCKVILLE, MD, (BUSINESS WIRE) -- BioReliance Corporation announced today that David A. Dodd has been named President, Chief Executive Officer and Chairman of the Board of the Company, effective today. BioReliance Corporation is a leading contract services company that provides biologics safety testing, toxicology, viral manufacturing and laboratory animal diagnostic services to the pharmaceutical and biopharmaceutical industries worldwide. Avista Capital Partners, a leading private equity firm, acquired BioReliance from Invitrogen (NASDAQ:IVGN) in April 2007. From 2000 through 2006, Mr. Dodd served as President and CEO of Serologicals Corporation, a publicly traded company that was sold to Millipore Corporation in 2006 for $1.4 billion. Prior to that, from 1995 he was President and CEO of Solvay Pharmaceuticals, Inc., a subsidiary of the Solvay Group. Mr. Dodd entered the pharmaceutical industry in 1977 when he joined Abbott Laboratories. He built on that foundation at McDonnell-Douglas Healthcare Systems, Bristol-Myers Squibb and Wyeth. Mr. Dodd currently serves as Non-executive Chairman of the Board at Stem Cell Sciences plc. (LSE:AIM: STEM; ASX: STC) "David brings an impressive record of maximizing the potential and competitive impact of the companies he manages," said David Burgstahler, a partner at Avista. ... "BioReliance is well known for its great legacy of pioneering science, strong regulatory expertise and innovative biologics safety services," said Mr. Dodd.
News 
Market Data 
Discover 
AI
